drugset / Trial / NCT06580444
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Phase 2
Not yet recruiting
40 enrolled
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Congressionally Directed Medical Research Programs · collabRTI International · collabSage Therapeutics · collabUnited States Department of Defense · collabVA Connecticut Healthcare System · collabYale University · collab
RandomizedParallel-groupTriple-blindOther
Summary
The purpose of this research study is to find out how Zulresso®/brexanolone influences Posttraumatic Stress Disorder (PTSD) symptoms and alcohol use.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2027-02-26
- Completion
- 2027-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brexanolone | Unknown | 30 ug/kg | Intravenous |
| Comparator | Brexanolone | Unknown | 60 ug/kg | Intravenous |
| Comparator | Brexanolone | Unknown | 90 ug/kg | Intravenous |